Zoetis Inc. (NYSE:ZTS) Shares Acquired by Bleakley Financial Group LLC

Bleakley Financial Group LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 15.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,351 shares of the company’s stock after acquiring an additional 1,612 shares during the period. Bleakley Financial Group LLC’s holdings in Zoetis were worth $2,012,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ZTS. Pensionfund Sabic increased its position in shares of Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares in the last quarter. PFW Advisors LLC acquired a new stake in Zoetis in the 4th quarter valued at $1,764,000. JPMorgan Chase & Co. increased its holdings in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after acquiring an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Zoetis during the third quarter worth $11,684,000. Finally, Nordea Investment Management AB lifted its holdings in Zoetis by 38.3% during the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZTS. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Morgan Stanley reduced their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $215.00.

Zoetis Trading Down 1.6 %

Shares of ZTS stock opened at $171.37 on Friday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company’s 50-day moving average price is $169.34 and its 200-day moving average price is $179.28. The stock has a market cap of $77.32 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 2.72 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.